tiprankstipranks
Prokidney Corp. (PROK)
NASDAQ:PROK
US Market
PROK
ProKidney
RESEARCH TOOLSreports
Want to see PROK full AI Analyst Report?

ProKidney (PROK) Stock News & Sentiment

367 Followers
Analyst Maintains Sell on ProKidney Amid Single-Asset Risk and Long Path to 2028 BLA, Keeps $1 Price Target Below Market
Premium
Ratings
Analyst Maintains Sell on ProKidney Amid Single-Asset Risk and Long Path to 2028 BLA, Keeps $1 Price Target Below Market
2d ago
PROK
ProKidney Highlights Progress in Pivotal Phase 3 CKD Trial
Premium
Company Announcements
ProKidney Highlights Progress in Pivotal Phase 3 CKD Trial
5d ago
8K
PROK
PROK Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
PROK Earnings Report this Week: Is It a Buy, Ahead of Earnings?
14d ago
PROK
Trade Policy Risks: How Evolving U.S. Tariffs and Export Rules Threaten ProKidney Corp.’s Supply Chain and Financial Stability
Premium
Company Announcements
Trade Policy Risks: How Evolving U.S. Tariffs and Export Rules Threaten ProKidney Corp.’s Supply Chain and Financial Stability
2M ago
PROK
ProKidney: Extended Development Timeline and Deferred Catalysts Support Balanced Hold Rating
Premium
Ratings
ProKidney: Extended Development Timeline and Deferred Catalysts Support Balanced Hold Rating
2M ago
PROK
Optimized PROACT 1 Design, Preserved Statistical Power, and Clear Regulatory Path Support Buy Rating on ProKidney
Premium
Ratings
Optimized PROACT 1 Design, Preserved Statistical Power, and Clear Regulatory Path Support Buy Rating on ProKidney
4M ago
PROK
ProKidney: Preserved Long-Term Opportunity but Heightened Timeline Risk Supports Continued Hold Rating
Premium
Ratings
ProKidney: Preserved Long-Term Opportunity but Heightened Timeline Risk Supports Continued Hold Rating
4M ago
PROK
More PROK News >

PROK News on the Web

ProKidney (PROK) Receives a Buy from Guggenheim
TipRanks News
Bullish
Is ProKidney (PROK) Attractive After Q1 2026 Beat? EPS -$0.14 vs -$0.15 est (beat); Revenue $0. ...
GuruFocus News
Bullish
Analysts’ Opinions Are Mixed on These Healthcare Stocks: BioMarin Pharmaceutical (BMRN) and ProKidney (PROK)
TipRanks News
Bullish
Analyst Maintains Sell on ProKidney Amid Single-Asset Risk and Long Path to 2028 BLA, Keeps $1 Price Target Below Market
TipRanks News
Neutral
ProKidney (PROK) Reports Q1 Earnings, EPS Beats Expectations
GuruFocus News
Bullish
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Insulet (PODD), ProKidney (PROK) and CG Oncology, Inc. (CGON)
TipRanks News
Neutral
Is ProKidney (PROK) Fairly Priced After Q1 2026? EPS -$0.14 Meets; Revenue $0.226M Beats $0. ...
GuruFocus News
Neutral
ProKidney Highlights Progress in Pivotal Phase 3 CKD Trial
TipRanks News
Neutral

News Score - Last 7 Days

Very Positive
PROK
Sector Average
Media Buzz
This Week10 articles
Weekly Average0.25 articles
News Sentiment
This Week99%
Sector Average77%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is PROK’s Media Buzz Sentiment?
10 articles about PROK were published this week. In an average week, 0.25 articles are published.
    What is PROK’s weekly average amount of articles?
    In an average week, 0.25 articles about PROK are published.
      What is PROK’s News Sentiment?
      99% of articles about PROK were positive this week, compared to its sector average of 77%.
        Healthcare Stocks that are Trending in the News
        DOCSDoximity
        AVAHAveanna Healthcare Holdings
        GOSSGossamer Bio
        CGENCompugen
        RLAYRelay Therapeutics
        Showing the stocks with the most bullish news sentiment over the past week